Media headlines about Xenon Pharmaceuticals (NASDAQ:XENE) have trended somewhat positive this week, Accern Sentiment reports. Accern scores the sentiment of news coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Xenon Pharmaceuticals earned a daily sentiment score of 0.25 on Accern’s scale. Accern also assigned news coverage about the biopharmaceutical company an impact score of 47.9695678801171 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

Several research analysts recently weighed in on XENE shares. Zacks Investment Research raised shares of Xenon Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, September 21st. Jefferies Group LLC set a $5.00 target price on shares of Xenon Pharmaceuticals and gave the company a “buy” rating in a research note on Friday, August 4th.

Shares of Xenon Pharmaceuticals (NASDAQ:XENE) traded down $0.03 during mid-day trading on Friday, reaching $2.30. 19,632 shares of the company traded hands, compared to its average volume of 108,519. Xenon Pharmaceuticals has a 12-month low of $2.10 and a 12-month high of $9.95.

In other news, Director Mohammad Azab bought 15,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 15th. The stock was purchased at an average price of $2.22 per share, with a total value of $33,300.00. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 9.40% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This report was first posted by Watch List News and is the property of of Watch List News. If you are accessing this report on another publication, it was stolen and reposted in violation of U.S. & international copyright laws. The correct version of this report can be read at https://www.watchlistnews.com/xenon-pharmaceuticals-xene-receives-news-impact-score-of-0-25/1726205.html.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company. It is engaged in discovering and developing a pipeline of differentiated therapeutics for orphan indications. Its product pipeline includes: Glybera, TV-45070, GDC-0310, XEN901 (Nav1.6 inhibitor) and XEN1101. Glybera is used for the treatment of lipoprotein lipase deficiency (LPLD).

Insider Buying and Selling by Quarter for Xenon Pharmaceuticals (NASDAQ:XENE)

Receive News & Ratings for Xenon Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenon Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.